Blood vessel integrity becomes critically compromised during sepsis, but the molecular mechanisms driving this deadly cascade have remained elusive. New research reveals how a specific protein pathway systematically dismantles the barriers that normally keep blood vessels sealed, offering potential therapeutic targets for one of medicine's most challenging conditions.
The investigation identifies leucine-rich alpha-2-glycoprotein 1 (LRG1) as a key orchestrator of vascular breakdown during septic lung injury. When sepsis strikes, LRG1 relocates inside endothelial cells and recruits MARCH2, an enzyme that tags VE-cadherin proteins for destruction. VE-cadherin normally acts as molecular glue holding blood vessel walls together, but this ubiquitination process marks it for cellular degradation, causing vessels to become leaky and permeable.
This mechanism helps explain why sepsis patients develop such severe fluid accumulation in their lungs and other organs. The systematic breakdown of VE-cadherin junctions allows blood plasma to flood into tissues where it doesn't belong, contributing to organ dysfunction and the high mortality rates associated with septic shock. Understanding this pathway represents a significant advance in sepsis research, where effective treatments have remained frustratingly limited despite decades of investigation.
The findings suggest that targeting either LRG1 or MARCH2 could potentially preserve vascular integrity during sepsis. However, any therapeutic applications would need careful development, as these proteins likely serve important physiological functions under normal conditions. The research also highlights how cellular location matters critically – LRG1's pathological effects appear specifically tied to its intracellular presence during inflammatory conditions.